ABSTRACT Using optimal culture conditions in which the transforming growth factor 11 (TGF-j1) inhibitory loop has been interrupted by antiuense TGF-131 oligonudeotides or antf-TGF-1 serum, we have compared the proliferative capacities and the abUities ofthe CD34+ CD38-ceil populations from bone marrow and umbilical cord blood to generate early progenitors in long-term cultures. The CD34+ CD38-fraction of umbilical cord blood accounts for 4% of the CD34+ fraction compared to only 1% in bone marrow, indicating that umbilical cord blood may be relatively enriched in stem cells. We estimate that the CD34+ CD38-cells from a typical umbilical cord blood sample produce equivalent numbers of colonyformdngunits (CFU)-gnulocyte/erythrocyte/macrophage/ megakaryocyt, twice as many CFU-granulocyte/macrophage (GM) and 3 times as many burst-forming units-erythroid as the same population from an average bone marrow sample used in adult tansplantation. In addition, the colonies resulting from the umbical cord blood samples were signiflcantly larger than those from bone marrow, indicating a greater growth potential. However, the content of later progenitors, which may be important for short-term reconstitution, was less in umbilical cord blood-derived than in bone marrow-derived cell preparatons, as esimated by a 4-fold lower production of CFU-GM in long-term cultures of CD34+ CD38+ cells. This deficit is pardaly compensated by the higher growth capacity of the resulting CFU-GM. These studies suggest that umbiical cord blood is a suitable source of cells for adult transplantation.
Small amounts of near-term or neonatal mouse blood has been demonstrated to have the potential to completely reconstitute the hematopoietic system of adult mice (1) . This finding has prompted extensive analysis of human umbilical cord blood as a potential source for cells for hematopoietic reconstitution in man (1) (2) (3) (4) . Various nonmalignant (3, 5) and malignant (7, 8) hematopoietic diseases and malignant nonhematopoietic diseases (9, 10) have been successfully treated in children by using umbilical cord blood transplantation. Umbilical cord blood is easily obtainable and therefore could be used to develop banks of HLA-typed cells for general use in adult transplantation ifthe engraftment potential were high enough. Here we report methods for evaluating the relative potentials for engraftment and their use in comparing umbilical cord blood and bone marrow as cellular sources for transplantation.
In the past, engraftability of bone marrow samples has largely been analyzed through estimation of the content of colony-forming unit (CFU)-anulocyte/macrophage (GM) (11, 13) . However, these cells, which are likely to play a role in cell generation for a short period following transplantation, may not accurately reflect the content of the more primitive cells that are important for long-term hematopoiesis. The
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. stem cells involved in long-term engraftment represent a small subset of cells in the CD34+ CD38-fraction of bone marrow (14, 15) . As many of these cells are quiescent, cultures on stromal layers (16) or specific preculture conditions (17) (18) (19) are required to release them from quiescence. However, in analyzing colony formation by cultured normal human bone marrow cells, we found that many early colonyforming cells (half or more) produce autocrine transforming growth factor p1 (TGF-,B1) and that these cells could not be triggered into cycle by the optimal concentrations of growth factors [interleukin (IL) 3, IL-6, granulocyte colonystimulating factor (G-CSF), and erythropoietin] (20) . We have further shown that, although inclusion of steel factor (SLF) increases the frequency of colony formation by early progenitor cells, it still does not reverse the effects ofTGF-,B1 in culture, and many cells remain quiescent (21 Purfication of CD34+ Cells. Mononuclear cells were obtained as described (20, 23) . Hematopoietic progenitors expressing the CD34 antigen were purified using the Applied Immune Sciences (Santa Clara, CA) procedure [soybean agglutinin (SBA) and CD34 CELLector flasks] (20, 24) . These cells were then recovered, concentrated, and used for fluorescence-activated cell sorting (FACS), phenotypic analAbbreviations: TGF-,B1, transforming growth factor ,B1; CFU, colony-forming unit(s); CFU-GEMM, CFU-granulocyte/erythrocyte/ macrophage/megakaryocyte; BFU-E, burst-forming unit(s)-erythroid; CFU-GM, CFU-ganulocyte/macrophage; IL, interleukin; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte/macrophage colony-stimulating factor; SLF, steel factor; rh, recombinant human; FACS, fluorescence-activated cell sorting.
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FACS. The starting populations for the cell sorting were the SBA-or the SBA-CD34+ fractions. In either case, the cell suspension was incubated with the fluorescein isothiocyanate-conjugated monoclonal antibody CD34 (clone 8G12; Becton Dickinson) and the phycoerythrin-conjugated monoclonal antibody CD38 (Leul7; Becton Dickinson) for 30 min at 4°C and washed twice. Then, the CD34+ CD38-and the CD34+ CD38+ cells were sorted using a Coulter Elite. Purity was consistently >99%o for both sorted populations (CD34+ CD38-and CD34+ CD38+ cells).
Cell numbers used in Table 2 (ii) To calculate the CD34+ fraction recovered after Ficoll and panning, we used the mean percentage of our routinely achieved yields, which represent 0.35% ± 0.08% of total bone marrow nucleated cells (mean ± 1 SE from 16 experiments) and 0.18% ± 0.05% oftotal umbilical cord blood cells (mean ± 1 SE from 50 experiments).
(iii) To calculate the CD34+ CD38-fraction recovered after FACS, we considered the mean percentage obtained, which represents 1% of the CD34+ fraction for bone marrow (mean from three experiments) and 4% of the CD34+ fraction for umbilical cord blood (mean from four experiments).
Cytokines and Progenitor Cultures. We have demonstrated that the low concentrations of cytokines used in these studies were necessary to avoid down-regulation of some receptors on immature cells (6) . These low concentrations of cytokines were always found equally optimal for bone marrow and umbilical cord blood early progenitors.
Liquid Primary Cultures. FACS-sorted CD34+ CD38-and CD34+ CD38+ cells were plated at 1000 cells per ml in Iscove's modified Dulbecco's medium supplemented with 30% fetal calf serum, 2 mM glutamine (Biochrom, Angouleme, France), iron-saturated transferrin (Sigma) at 10 pg/mi, deionized bovine serum albumin (Sigma) at 1 mg/ml, 50 pM 2-mercaptoethanol (Merck), rhIL-3 at 1.7 units/ml, rhIL-6 at 10 units/ml, and rhG-CSF at 3 units/ml. When indicated, rhSLF (6 ng/ml) and/or anti-TGF-,B serum (4.2 Ad/ml) were used. Every 7 days the number of viable cells was determined, and a sample was removed for clonogenic assays. Half of the culture was replaced by fresh medium. In calculating the number of cells, a correction factor was applied to compensate for cells removed at previous time points.
Clonogenic Assays. The enriched CD34+ cells were cultured at 750-1000 cells per ml for bone marrow and 300-400 cells per ml for umbilical cord blood according to a modification (20) of the mixed colony assay of Fauser and Messner (12) . rhSLF (6 ng/ml) was included in our standard assay. All the cultures were performed in triplicate or quadruplicate. In the expansion studies from the CD34+ CD38-and CD34+ CD38+ cells, clonogenic assays corresponding to each time point were performed as described above.
Colony Classification. Colonies were classified as described (12, 23) . In the secondary clonogenic assays following the primary liquid cultures, CFU-GM, burst-forming unit(s)-erythroid (BFU-E), and CFU-granulocyte/erythrocyte/ macrophage/megakaryocyte (CFU-GEMM) colonies were counted when they had more than 5 x 102, 6 x 103, and 104 cells, respectively. These cutoffs resulted in exclusion of fewer than 10% of each colony type. The numbers of progenitors were calculated by multiplying their frequency deduced from clonogenic assay by the corrected number of nucleated cells present in the liquid cultures at each point.
Statistical Analysis. The significance of differences between treatment groups was determined using the paired Student's t test.
RESULTS

Effects of Antisense TGF-,B1 on Proliferation of Umbilical
Cord Blood-Derived CD34+ CD38-and CD34+ CD38+ Ceils.
The surface antigen for maturing progenitors, CD38, has been used to separate the CD34+ cell fraction into an immature quiescent fraction believed to contain the stem cells (CD34+ CD38-) and a fraction of later, committed progenitors (CD34+ CD38+) (14) . The more primitive CD34+ CD38-cell fraction is more abundant in cord blood than in bone marrow: 4% ± 1% of the CD34+ cord blood cell preparation but only 1% of comparable bone marrow cell preparations (data not shown). When cultured in the presence of IL-3, IL-6, GM-CSF, SLF, and erythropoietin, colony formation by early progenitors (CFU-GEMM, high proliferative potential colony-forming cells, and early BFU-E) in the cord blood CD38-fraction, but not in the CD38+ fraction, was significantly (1.5-to 2-fold) enhanced by an antisense TGF-181 oligodeoxynucleotide (Table 1 The values correspond to one experiment representative of three similar ones and represent the mean ± 1 SE of three dishes (300 cells per ml). HPP-CFC, high proliferative potential colony-forming cell; oligo, oligodeoxynucleotide; Epo, erythropoietin. *P < 0.01 CD34+ CD38-vs. CD34+ CD38+. tp <U.yO CD34+ CD38-vs. CD34+ CD38+.
*CFU-erythroid, -qacrophage, and -granulocyte.
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CD38+ fractions from CD34+ bone marrow and cord blood cell preparations, 1000 cells of each type were seeded in liquid suspension culture containing IL-3, IL-6, and G-CSF with or without SLF and with or without anti-TGF-( serum. After every 7 days in culture, half of the culture medium was removed and replaced with fresh medium. The removed cells were counted and plated in semisolid methylcellulose culture to enumerate the cycling progenitors generated in the primary culture.
As shown in Figs. 1A and 2A, CD34+ CD38-cells, when grown under optimal conditions, were much more effective in total cell generation than were CD38+ cells. With either cord blood-or bone marrow-derived progenitors, the optimal growth conditions included both SLF and anti-TGF-,B serum, although the effect of the antibody, particularly with the cord blood cells, was much less than the effect of SLF. Under optimal conditions, peak total cell amplification occurred at 28-35 days in culture: 14,000-fold with cord blood cells and 3600-fold with the bone marrow cells. In contrast, the corresponding CD38+ cell fractions yielded 1500-and 1100-fold increases in total cell number with cells from cord blood and bone marrow, respectively, during the same time period.
Analysis of progenitor cell generation revealed that the combination of SLF and anti-TGF-, serum with CD34+ CD38-cells was generally optimal with all of the different colony types from either cord blood (Fig. 1 ) or bone marrow (Fig. 2) . The total CFU-GM production, which continued until 35-42 days in the presence of both agents, was substantially greater with the cord blood than the bone marrow: in the former case, 1000 initial cells yielded 44,000 CFU-GM but only 5800 in the latter. The corresponding CD38+ populations yielded only 835 and 242 CFU-GM (Figs. 1B and 2B) from cord blood and bone marrow, respectively, and the generation ofthese progenitors ceased after 7 days ofculture. Days in liquid culture 7
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As with CFU-GM, CD34+ CD38-cells from both bone marrow and cord blood were much more effective in generating early BFU-E (Figs. 1C and 2C ) and CFU-GEMM (Figs. 1D and 2D) than were CD38+ cells grown under optimal conditions. Anti-TGF-B serum alone was more effective than SLF in enhancing the production of BFU-E and CFU-GEMM in contrast with CFU-GM generation. However, the combination ofthe two agents in general both accelerated and extended the time of progenitor production, resulting in increased accumulation of the colony-forming cells during the life of the cultures. Under optimal conditions, the cord blood CD38-cells (Fig. 1 C and D) were much more effective than the comparable bone marrow-derived cells (Fig. 2 C and  D (Figs. 1 and 2 ). In addition, the mixed colonies grown in secondary culture of the CD38+ cord blood cells were smaller than the corresponding colonies grown from either of the CD38-preparations. In addition, all of the progenitors generated from the bone marrow CD38+ cell preparations (CFU-GM, BFU-E, and CFU-GEMM) yielded smaller colonies on secondary plating than the progenitors from any of the other cell preparations (CD38-cord blood and bone marrow and CD38+ cord blood) (data not shown).
Although a typical bone marrow sample prepared for adult bone marrow transplant contains significantly more CD34+ cells than a typical cord blood sample (100-200 ml), the total abilities of cells from the two sources to generate early progenitors in primary culture are quite comparable (Table  2) . This results from the higher frequency of CD34+ CD38- cells in the cord blood preparations and from the higher proliferative potential of these cells in culture. In fact, the CD34+ CD38-cord blood fraction yielded slightly fewer CFU-GEMM but almost 3-fold more early BFU-E and 2-fold more CFU-GM than did the corresponding bone marrow cell preparation. Because the CD34+ CD38+ fraction is 14.6-fold more abundant in bone marrow than in cord blood, the total capacity for generation of all colony types is significantly greater in bone marrow (Table 2 ). However, most of the progenitors from the CD34+ CD38+ bone marrow cells developed quickly (within 7 days) in primary culture and yielded only small colonies on replating.
DISCUSSION
In this study, we used optimal culture conditions for measuring the capacity of early human hematopoietic cells for generating progenitors in culture, and we have compared the relative proliferative capacities of adult bone marrow and umbilical cord blood. The effects of antisense TGF-(1 oligodeoxynucleotides on colony formation were largely restricted to the CD34+ CD38-and not the CD34+ CD38+ cell fractions from both cord blood and bone marrow. These findings are consistent with the demonstration by others that CD38 is expressed by differentiating progenitors (14) and that a higher proportion of the CD34+ CD38-cell population, which includes the stem cell compartment, is quiescent. In cultures supplemented with antisense TGF-,B1 oligodeoxynucleotides and SLF, our cord blood CD34+ CD38-cell preparations typically had cloning efficiencies of -45%, and 75% of the resulting colonies were large, reflecting the early stage of development of the founding progenitors. The CD34+ CD38-fraction from umbilical cord blood was much more effective in generating early progenitors in long-term culture than was the corresponding fraction from bone marrow, which was, in turn, much more effective than the CD38+ fractions from either cell source.
Although a typical bone marrow sample used in adult transplantation has 10-to 15-fold more CD34+ cells than a typical umbilical cord blood sample, the 4-fold higher frequency of CD38-cells in the CD34+ fraction of umbilical cord blood and the greater proliferative capacity of these cells relative to their bone marrow counterparts suggest that cord blood might be a useful source for cells for bone marrow transplantation in adults. In the past, the engraftment potential of different samples has been estimated by measuring CFU-GM levels. Although the numbers of these late progenitors may sometimes also correlate with the number of early progenitors, this may not always be the case, and these late progenitors are unlikely by themselves to be capable of sustaining long-term engraftment. Our comparison of CD34+ CD38-cells from umbilical cord blood and bone marrow in fact indicates that the CD34+ CD38-cells from an average umbilical cord blood sample can produce comparable numbers ofCFU-GEMM, 3 times more early BFU-E, and 2 times more large CFU-GM than can the corresponding cell fractions from bone marrow. These findings indicate that the long-term engraftment capacity of 100-200 ml of cord blood 
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